"The combination of transformational technologies found in Watson with our cancer analytics and decision-making process has the potential to revolutionize the accessibility of information for the treatment of cancer in communities across the country and around the world," MSKCC CEO Craig Thompson said in a statement. "
IBM and MSKCC oncologists are already beginning development of the first applications to Watson, which include lung, breast and prostate cancers.
The objective is to begin piloting the applications for a select group of oncologists in late 2012, with wider distribution planned for late 2013.
Lucas Mearian covers storage, disaster recovery and business continuity, financial services infrastructure and health care IT for Computerworld. Follow Lucas on Twitter at @lucasmearian , or subscribe to Lucas's RSS feed . His e-mail address is firstname.lastname@example.org .
Read more about healthcare it in Computerworld's Healthcare IT Topic Center.